Epi-liquidomics: redefining cancer diagnostics through epigenetic profiling.

Early detection is central to reducing cancer related morbidity and mortality, as timely intervention significantly improves curative potential. However, conventional diagnostic modalities such as imaging and tissue biopsy often lack sensitivity for early-stage disease and are inherently invasive. To address these limitations, we introduce Epi-Liquidomics, defined as the comprehensive profiling of circulating epigenetic alterations including DNA methylation patterns, histone derived nucleosome signatures, chromatin fragmentation landscapes and non-coding RNA cargo to enable non-invasive cancer diagnostics supported by advancing technologies. Emerging preclinical and clinical evidence indicates that tumor associated DNA methylation and cfDNA fragmentation signatures are detectable even in stage I-II cancers, directly supporting their applicability in early disease identification rather than solely conceptual potential. By integrating multi-layered epigenetic signals into liquid biopsy platforms, Epi-Liquidomics enhances cancer detection in low tumor-fraction settings and enables accurate tissue-of-origin prediction, offering advantages over mutation centric genomic assays. Beyond early diagnosis, Epi-Liquidomics provides insights into tumor biology by capturing dynamic regulatory states and microenvironment-associated alterations, facilitating improved risk stratification and longitudinal disease monitoring. This framework supports real-time assessment of therapeutic response and detection of minimal residual disease. Importantly, its current limitations including false-positive rates in population screening, assay standardization, and biological variability underscore the need for rigorous prospective validation before routine clinical implementation. As sequencing technologies and computational tools continue to advance, Epi-Liquidomics holds strong translational potential to refine cancer screening and advance minimally invasive precision oncology.